{
    "GTBL": [
        "The stock has given close to 2200% returns in the last five years.",
        "The company's revenues have been growing at an extremely high rate, with margins and earnings per share also increasing significantly.",
        "The stock's PE is currently at 19, compared to the Nifty Pharma PE of 31, suggesting it is undervalued.",
        "The PEG ratio of the stock is less than one, indicating it is undervalued.",
        "The company has a high price to intrinsic value rank, suggesting it is undervalued compared to other stocks on the exchange.",
        "The company has a low debt to equity ratio and high promoter holding, indicating low risk."
    ],
    "username": "Rahul Jain"
}